Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Table 3

Adverse events in 3 groups.

	DOX 93			XELOX 92			Surgery 95
	Grades 1-2	Grade 3	Grade 4	Grades 1-2	Grade 3	Grade 4	Grades 1-2	Grade 3	Grade 4
Gastrointestinal disorders
Nausea	41	14	0	36	15	0	38	12	0
Vomiting	20	4	0	10	2	0	12	0	0
Diarrhea	34	6	0	26	2	0	16	6	0
Constipation	8	0	0	8	0	0	4	0	0
Decreased appetite	46	8	0	38	8	0	40	6	0
Dysphagia
Blood and lymphatic system disorders
Anemia	44	6	2	44	2	0	38	4	0
Leucopenia	54	16	4	50	17	4	46	15	0
Neutropenia	59	24	6	48	26	2	40	18	2
Thrombocytopenia	22	4	2	16	0	0	18	0	0
Febrile neutropenia	NA	2	0	NA	0	0	NA	0	0
General and other disorders
Neurotoxic effects	14	0	0	12	0	0	8	0	0
Fatigue	46	10	0	38	7	0	34	8	0
Alopecia	58	NA	NA	0	NA	NA	0	NA	NA
Weight decreased	34	4	0	38	0	0	28	0	0
Skin effects	8	0	0	4	0	0	2	0	0
Laboratory
ALT elevation	14	2	0	10	0	0	8	0	0
GOT elevation	10	2	0	12	0	0	10	0	0